Cameron’s Law

1. 01

   How would doubling the tax credit from 25% to 50% change which rare diseases attract pharmaceutical investment versus those that remain neglected?

2. 02

   What evidence suggests that a higher tax credit will meaningfully accelerate drug development for orphan diseases compared to other incentive structures?

3. 03

   If this tax credit costs the government foregone revenue, how should policymakers weigh that fiscal trade-off against potential benefits for patients with rare diseases?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.